Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueDepreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - Net
Ratios

Harmony Biosciences Holdings (HRMY) EBIAT (2019 - 2025)

Harmony Biosciences Holdings' EBIAT history spans 7 years, with the latest figure at $22.5 million for Q4 2025.

  • For Q4 2025, EBIAT fell 54.55% year-over-year to $22.5 million; the TTM value through Dec 2025 reached $158.7 million, up 9.07%, while the annual FY2025 figure was $158.7 million, 9.07% up from the prior year.
  • EBIAT for Q4 2025 was $22.5 million at Harmony Biosciences Holdings, down from $50.9 million in the prior quarter.
  • Across five years, EBIAT topped out at $87.9 million in Q3 2022 and bottomed at -$9.6 million in Q3 2021.
  • The 5-year median for EBIAT is $31.9 million (2023), against an average of $32.5 million.
  • The largest YoY upside for EBIAT was 52385.19% in 2021 against a maximum downside of 603.93% in 2021.
  • A 5-year view of EBIAT shows it stood at $22.7 million in 2021, then skyrocketed by 113.56% to $48.5 million in 2022, then crashed by 45.15% to $26.6 million in 2023, then skyrocketed by 85.95% to $49.5 million in 2024, then tumbled by 54.55% to $22.5 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's EBIAT are $22.5 million (Q4 2025), $50.9 million (Q3 2025), and $39.8 million (Q2 2025).